Semaglutide initiation significantly cuts mortality, hospitalization, and adverse events in MASLD patients vs. SGLT2is
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition strongly linked to cardiometabolic comorbidities like type 2 diabetes and obesity. Despite its widespread impact, effective pharmacological treatments specifically approved for MASLD are limited, leading to a significant unmet clinical need. Current standard-of-care often focuses on managing associated conditions, but direct therapies targeting liver outcomes are emerging. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown promise in improving metabolic health and reducing cardiovascular and renal risks, making them compelling candidates for MASLD management.
Study Design
This multicenter, retrospective, propensity score-matched cohort study utilized real-world data from the TriNetX U.S. Collaborative Network. Researchers identified adults with MASLD and at least one metabolic comorbidity who were new initiators of semaglutide (n=128,332) or SGLT2is (n=100,542). After excluding confounding liver etiologies, one-to-one propensity score matching on over 50 covariates created balanced cohorts of 55,525 patients each. Time-to-event outcomes, including all-cause mortality, hospitalization, major adverse cardiovascular events (MACE), major adverse liver outcomes (MALO), and major adverse kidney events (MAKE), were evaluated at 1-year and 5-year follow-ups using Kaplan-Meier analysis and Cox proportional hazards models.
Results
Initiating semaglutide was associated with significant risk reductions across multiple endpoints compared to SGLT2is. At 1-year, semaglutide demonstrated substantial benefits: all-cause mortality was reduced with a hazard ratio (HR) of 0.382 (95% CI 0.338-0.430), all-cause hospitalization with an HR of 0.444 (95% CI 0.429-0.459), and MACE with an HR of 0.502 (95% CI 0.476-0.530). The most pronounced effect was on MALO, showing an HR of 0.361 (95% CI 0.316-0.412).
Key Findings
- Semaglutide initiation reduced all-cause mortality by 61.8% (HR 0.382) at 1-year vs. SGLT2is.
- All-cause hospitalization was cut by 55.6% (HR 0.444) at 1-year with semaglutide.
- Major adverse liver outcomes (
MALO) decreased by 63.9% (HR 0.361) at 1-year with semaglutide. - Major adverse cardiovascular events (
MACE) were reduced by 49.8% (HR 0.502) at 1-year with semaglutide. - At 5-years, semaglutide maintained significant reductions across mortality (HR 0.494), hospitalization (HR 0.565), and
MALO(HR 0.494).
Why It Matters
This large real-world study provides compelling evidence that semaglutide may offer superior benefits over SGLT2 inhibitors for MASLD patients across a spectrum of critical outcomes. For clinicians and individuals managing MASLD, this suggests that GLP-1RAs like semaglutide could be a preferred first-line option, especially when considering the broad cardiometabolic and hepatic protection. The significant reductions in mortality, hospitalization, and major adverse events highlight a potential shift in treatment paradigms. While this is a real-world observational study, the robust propensity matching strengthens its implications, moving us closer to understanding optimal therapeutic sequencing. Further randomized controlled trials are needed to confirm these findings and establish definitive clinical guidelines, but this data strongly supports the comprehensive benefits of GLP-1R agonism in this population.
semaglutide
masld
sglt2i
cardiovascular
hepatic
mortality